skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index
Refined by: Journal Title: The Lancet remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Material Type:
Article
Add to My Research

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

The Lancet (British edition), 2017-04, Vol.389 (10077), p.1399-1409 [Peer Reviewed Journal]

Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Apr 8, 2017 ;2017. Elsevier Ltd ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)30069-7 ;PMID: 28237263

Full text available

2
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Material Type:
Article
Add to My Research

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

The Lancet (British edition), 2005-10, Vol.366 (9493), p.1279-1289 [Peer Reviewed Journal]

2005 Elsevier Ltd ;Copyright Lancet Ltd. Oct 8-Oct 14, 2005 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(05)67528-9 ;PMID: 16214598 ;CODEN: LANCAO

Full text available

3
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Material Type:
Article
Add to My Research

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

The Lancet (British edition), 2006-11, Vol.368 (9548), p.1660-1672 [Peer Reviewed Journal]

2006 Elsevier Ltd ;Copyright Lancet Ltd. Nov 11-Nov 17, 2006 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(06)69571-8 ;PMID: 17098084 ;CODEN: LANCAO

Full text available

4
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Material Type:
Article
Add to My Research

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

The Lancet (British edition), 2005-04, Vol.365 (9468), p.1389-1397 [Peer Reviewed Journal]

2005 Elsevier Ltd ;Copyright Lancet Ltd. Apr 16-Apr 22, 2005 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(05)66374-X ;PMID: 15836887 ;CODEN: LANCAO

Full text available

5
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
Material Type:
Article
Add to My Research

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

The Lancet (British edition), 2010, Vol.376 (9740), p.517-523 [Peer Reviewed Journal]

Elsevier Ltd ;2010 Elsevier Ltd ;2015 INIST-CNRS ;Copyright 2010 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Aug 14-Aug 20, 2010 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(10)60935-X ;PMID: 20709233 ;CODEN: LANCAO

Full text available

6
Gliptin versus a sulphonylurea as add-on to metformin
Material Type:
Article
Add to My Research

Gliptin versus a sulphonylurea as add-on to metformin

The Lancet (British edition), 2012-08, Vol.380 (9840), p.450-452 [Peer Reviewed Journal]

Elsevier Ltd ;2012 Elsevier Ltd ;Copyright Elsevier Limited Aug 4-Aug 10, 2012 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)60859-9 ;PMID: 22748818 ;CODEN: LANCAO

Full text available

7
Which incretin-based therapy for type 2 diabetes?
Material Type:
Article
Add to My Research

Which incretin-based therapy for type 2 diabetes?

The Lancet (British edition), 2014-10, Vol.384 (9951), p.1325-1327 [Peer Reviewed Journal]

Elsevier Ltd ;2014 Elsevier Ltd ;Copyright Elsevier Limited Oct 11, 2014 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)61097-7 ;PMID: 25018117 ;CODEN: LANCAO

Full text available

8
Addition of incretin therapy to metformin in type 2 diabetes
Material Type:
Article
Add to My Research

Addition of incretin therapy to metformin in type 2 diabetes

The Lancet (British edition), 2010-04, Vol.375 (9724), p.1410-1412 [Peer Reviewed Journal]

Elsevier Ltd ;2010 Elsevier Ltd ;Copyright Elsevier Limited Apr 24-Apr 30, 2010 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(10)60399-6 ;PMID: 20417840 ;CODEN: LANCAO

Full text available

9
Exenatide once weekly in type 2 diabetes
Material Type:
Article
Add to My Research

Exenatide once weekly in type 2 diabetes

The Lancet (British edition), 2008-10, Vol.372 (9645), p.1197-1198 [Peer Reviewed Journal]

Elsevier Ltd ;2008 Elsevier Ltd ;Copyright Elsevier Limited Oct 4-Oct 10, 2008 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(08)61207-6 ;PMID: 18782642 ;CODEN: LANCAO

Full text available

10
Efficacy and safety of the weight-loss drug rimonabant
Material Type:
Article
Add to My Research

Efficacy and safety of the weight-loss drug rimonabant

The Lancet (British edition), 2008-02, Vol.371 (9612), p.555-555 [Peer Reviewed Journal]

Elsevier Ltd ;2008 Elsevier Ltd ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(08)60261-5 ;PMID: 18280320

Full text available

11
Voglibose for prevention of type 2 diabetes mellitus
Material Type:
Article
Add to My Research

Voglibose for prevention of type 2 diabetes mellitus

The Lancet (British edition), 2009-05, Vol.373 (9675), p.1579-1580 [Peer Reviewed Journal]

Elsevier Ltd ;2009 Elsevier Ltd ;Copyright Elsevier Limited May 9-May 15, 2009 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(09)60575-4 ;PMID: 19395080 ;CODEN: LANCAO

Full text available

12
Does the metabolic syndrome help to select patients requiring high statin dose?
Material Type:
Article
Add to My Research

Does the metabolic syndrome help to select patients requiring high statin dose?

The Lancet (British edition), 2006-09, Vol.368 (9539), p.893-894 [Peer Reviewed Journal]

2006 Elsevier Ltd ;Copyright Lancet Ltd. Sep 9-Sep 15, 2006 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(06)69293-3 ;PMID: 16962860 ;CODEN: LANCAO

Full text available

13
VALUE: analysis of results
Material Type:
Article
Add to My Research

VALUE: analysis of results

The Lancet (British edition), 2004-09, Vol.364 (9438), p.932-933 [Peer Reviewed Journal]

2004 Elsevier Ltd ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(04)17012-8 ;PMID: 15364179

Full text available

14
Fungal contamination in barley and Kashin-Beck disease in Tibet
Material Type:
Article
Add to My Research

Fungal contamination in barley and Kashin-Beck disease in Tibet

The Lancet (British edition), 1997-10, Vol.350 (9084), p.1074-1074 [Peer Reviewed Journal]

1997 Elsevier Ltd ;1997 INIST-CNRS ;Copyright Lancet Ltd. Oct 11, 1997 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(05)70453-0 ;PMID: 10213552 ;CODEN: LANCAO

Full text available

15
Acarbose for type 2 diabetes prevention
Material Type:
Article
Add to My Research

Acarbose for type 2 diabetes prevention

The Lancet (British edition), 2002-11, Vol.360 (9344), p.1516-1516 [Peer Reviewed Journal]

2002 Elsevier Ltd ;Copyright National Library of Medicine - MEDLINE Abstracts Nov 9 2002 ;Copyright Elsevier Limited Nov 9, 2002 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(02)11457-7 ;PMID: 12433557 ;CODEN: LANCAO

Full text available

16
Effects of human growth hormone therapy on melanocytic naevi
Material Type:
Article
Add to My Research

Effects of human growth hormone therapy on melanocytic naevi

The Lancet (British edition), 1993-06, Vol.341 (8859), p.1505-1506 [Peer Reviewed Journal]

1993 ;1993 INIST-CNRS ;Copyright Lancet Ltd. Jun 12, 1993 ;Copyright Elsevier Limited Jun 12, 1993 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/0140-6736(93)90636-U ;PMID: 8099381 ;CODEN: LANCAO

Full text available

17
Non-alcoholic steatohepatitis
Material Type:
Article
Add to My Research

Non-alcoholic steatohepatitis

The Lancet (British edition), 1999-10, Vol.354 (9186), p.1298-1298 [Peer Reviewed Journal]

1999 Elsevier Ltd ;Copyright National Library of Medicine - MEDLINE Abstracts Oct 9 1999 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(05)76068-2 ;PMID: 10520658 ;CODEN: LANCAO

Full text available

18
Serum-gonadotrophins after oxytocin in man
Material Type:
Article
Add to My Research

Serum-gonadotrophins after oxytocin in man

The Lancet (British edition), 1968-09, Vol.2 (7570), p.735-735 [Peer Reviewed Journal]

ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;PMID: 4175113

Full text available

Searching Remote Databases, Please Wait